Clinical Trial Update: Lenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma with High-risk Recurrence Factors [Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 2 neoadjuvant regimen for CNLC stage IB/IIA hepatocellular carcinoma with high-risk recurrence factors, combining l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• LENVIMA (lenvatinib)
• OXALIPLATIN (Oxaliplatin)
• Pharmorubicin (pharmorubicin)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Zhejiang Cancer Hospital | Conditions: Hepatocellular Carcinoma, Lenvatinib | Phase 2 | Status: RECRUITING